Is AURA or IMNM more profitable?

Immunome's return on equity of -50.56% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -73.18% -62.00% Immunome N/A -50.56% -46.93%

Does the media refer more to AURA or IMNM?

In the previous week, Immunome had 9 more articles in the media than Aura Biosciences. MarketBeat recorded 11 mentions for Immunome and 2 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.77 beat Immunome's score of 1.08 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Immunome 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ZLAB or AURA more profitable?

Aura Biosciences has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Zai Lab -41.86% -27.43% -16.72% Aura Biosciences N/A -73.18% -62.00%

Does the media favor ZLAB or AURA?

In the previous week, Zai Lab and Zai Lab both had 2 articles in the media. Aura Biosciences' average media sentiment score of 1.77 beat Zai Lab's score of 0.87 indicating that Aura Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Aura Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings and valuation, SLS or AURA?

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SELLAS Life Sciences Group N/A N/A -$26.86M -$0.21 N/A Aura Biosciences N/A N/A -$106.19M -$1.75 N/A

Is SLS or AURA more profitable?

SELLAS Life Sciences Group's return on equity of -35.91% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences Group N/A -35.91% -33.34% Aura Biosciences N/A -73.18% -62.00%

Does the media prefer SLS or AURA?

In the previous week, SELLAS Life Sciences Group had 3 more articles in the media than Aura Biosciences. MarketBeat recorded 5 mentions for SELLAS Life Sciences Group and 2 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.77 beat SELLAS Life Sciences Group's score of 0.80 indicating that Aura Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aura Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor BEAM or AURA?

In the previous week, Beam Therapeutics had 24 more articles in the media than Aura Biosciences. MarketBeat recorded 26 mentions for Beam Therapeutics and 2 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.77 beat Beam Therapeutics' score of 0.48 indicating that Aura Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aura Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor AURA or NRIX?

In the previous week, Nurix Therapeutics had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 3 mentions for Nurix Therapeutics and 2 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.77 beat Nurix Therapeutics' score of 0.99 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Nurix Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aura Biosciences (AURA) Competitors

$6.99 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$7.00 +0.00 (+0.07%)

As of 09/11/2026 07:30 PM Eastern

Compare

AURA vs. IMNM, ZLAB, SLS, BEAM, and NRIX

Should you buy Aura Biosciences stock or one of its competitors? Aura Biosciences's main competitors and comparable companies include Immunome (IMNM), Zai Lab (ZLAB), SELLAS Life Sciences Group (SLS), Beam Therapeutics (BEAM), and Nurix Therapeutics (NRIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aura Biosciences compare to Immunome?

Aura Biosciences (NASDAQ:AURA) and Immunome (NASDAQ:IMNM) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

Aura Biosciences has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, Immunome has a beta of 2.13, suggesting that its share price is 113% more volatile than the broader market.

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 1.9% of Aura Biosciences shares are owned by insiders. Comparatively, 7.2% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aura Biosciences has higher earnings, but lower revenue than Immunome. Immunome is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A
Immunome	$6.94M	403.75	-$212.39M	-$2.53	N/A

Aura Biosciences presently has a consensus target price of $17.50, suggesting a potential upside of 150.36%. Immunome has a consensus target price of $34.64, suggesting a potential upside of 40.40%. Given Aura Biosciences' higher probable upside, analysts clearly believe Aura Biosciences is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Immunome's return on equity of -50.56% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-73.18%	-62.00%
Immunome	N/A	-50.56%	-46.93%

In the previous week, Immunome had 9 more articles in the media than Aura Biosciences. MarketBeat recorded 11 mentions for Immunome and 2 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.77 beat Immunome's score of 1.08 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Immunome	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Immunome beats Aura Biosciences on 8 of the 14 factors compared between the two stocks.

How does Aura Biosciences compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Aura Biosciences (NASDAQ:AURA) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

In the previous week, Zai Lab and Zai Lab both had 2 articles in the media. Aura Biosciences' average media sentiment score of 1.77 beat Zai Lab's score of 0.87 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Aura Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Aura Biosciences has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-41.86%	-27.43%	-16.72%
Aura Biosciences	N/A	-73.18%	-62.00%

41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 4.9% of Zai Lab shares are owned by insiders. Comparatively, 1.9% of Aura Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aura Biosciences has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	5.97	-$175.54M	-$1.71	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A

Zai Lab has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

Zai Lab presently has a consensus price target of $37.25, suggesting a potential upside of 54.31%. Aura Biosciences has a consensus price target of $17.50, suggesting a potential upside of 150.36%. Given Aura Biosciences' higher possible upside, analysts plainly believe Aura Biosciences is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Zai Lab beats Aura Biosciences on 9 of the 15 factors compared between the two stocks.

How does Aura Biosciences compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and Aura Biosciences (NASDAQ:AURA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by company insiders. Comparatively, 1.9% of Aura Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, SELLAS Life Sciences Group had 3 more articles in the media than Aura Biosciences. MarketBeat recorded 5 mentions for SELLAS Life Sciences Group and 2 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.77 beat SELLAS Life Sciences Group's score of 0.80 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aura Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

SELLAS Life Sciences Group's return on equity of -35.91% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%
Aura Biosciences	N/A	-73.18%	-62.00%

SELLAS Life Sciences Group currently has a consensus target price of $10.00, indicating a potential downside of 13.42%. Aura Biosciences has a consensus target price of $17.50, indicating a potential upside of 150.36%. Given Aura Biosciences' higher possible upside, analysts plainly believe Aura Biosciences is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

SELLAS Life Sciences Group has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A

Summary

SELLAS Life Sciences Group beats Aura Biosciences on 6 of the 11 factors compared between the two stocks.

How does Aura Biosciences compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Aura Biosciences (NASDAQ:AURA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

Aura Biosciences has a net margin of 0.00% compared to Beam Therapeutics' net margin of -54.75%. Beam Therapeutics' return on equity of -30.71% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Aura Biosciences	N/A	-73.18%	-62.00%

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by insiders. Comparatively, 1.9% of Aura Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Beam Therapeutics has higher revenue and earnings than Aura Biosciences. Beam Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	17.73	-$79.99M	-$0.86	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A

Beam Therapeutics has a beta of 2.22, indicating that its stock price is 122% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

Beam Therapeutics currently has a consensus price target of $49.00, indicating a potential upside of 104.25%. Aura Biosciences has a consensus price target of $17.50, indicating a potential upside of 150.36%. Given Aura Biosciences' higher probable upside, analysts clearly believe Aura Biosciences is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Beam Therapeutics had 24 more articles in the media than Aura Biosciences. MarketBeat recorded 26 mentions for Beam Therapeutics and 2 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.77 beat Beam Therapeutics' score of 0.48 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aura Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Beam Therapeutics beats Aura Biosciences on 11 of the 15 factors compared between the two stocks.

How does Aura Biosciences compare to Nurix Therapeutics?

Aura Biosciences (NASDAQ:AURA) and Nurix Therapeutics (NASDAQ:NRIX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Aura Biosciences has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Aura Biosciences' return on equity of -73.18% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-73.18%	-62.00%
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

Aura Biosciences has higher earnings, but lower revenue than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A
Nurix Therapeutics	$83.98M	31.02	-$264.46M	-$3.45	N/A

96.8% of Aura Biosciences shares are held by institutional investors. 1.9% of Aura Biosciences shares are held by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aura Biosciences has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market.

Aura Biosciences currently has a consensus target price of $17.50, suggesting a potential upside of 150.36%. Nurix Therapeutics has a consensus target price of $34.21, suggesting a potential upside of 36.31%. Given Aura Biosciences' higher probable upside, equities research analysts plainly believe Aura Biosciences is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Nurix Therapeutics had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 3 mentions for Nurix Therapeutics and 2 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.77 beat Nurix Therapeutics' score of 0.99 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Nurix Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aura Biosciences beats Nurix Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Aura Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AURA vs. The Competition

Export

Metric	Aura Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$725.42M	$3.86B	$7.17B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-3.99	14.18	274.94	25.27
Price / Sales	N/A	1,374.95	633.23	90.48
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	3.24	15.12	10.33	6.20
Net Income	-$106.19M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-7.54%	-4.34%	-3.32%	-2.35%
1 Month Performance	-9.81%	-0.02%	-0.41%	-2.77%
1 Year Performance	13.11%	40.64%	19.21%	7.63%

Aura Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AURA Aura Biosciences	2.3388 of 5 stars	$6.99 flat	$17.50 +150.4%	+5.3%	$725.42M	N/A	N/A	50	Positive News
IMNM Immunome	3.1076 of 5 stars	$26.81 +0.2%	$34.64 +29.2%	+154.9%	$3.05B	$6.94M	N/A	40	Positive News Analyst Forecast
ZLAB Zai Lab	2.2986 of 5 stars	$25.41 -3.1%	$37.25 +46.6%	-25.7%	$2.89B	$449.61M	N/A	1,784
SLS SELLAS Life Sciences Group	0.384 of 5 stars	$13.96 +0.7%	$10.00 -28.4%	+511.1%	$2.82B	N/A	N/A	10
BEAM Beam Therapeutics	2.338 of 5 stars	$26.83 -9.5%	$49.00 +82.6%	+11.3%	$2.77B	$139.74M	N/A	510	Trending News Analyst Forecast Options Volume High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AURA) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aura Biosciences (AURA) Competitors

AURA vs. IMNM, ZLAB, SLS, BEAM, and NRIX

How does Aura Biosciences compare to Immunome?

Summary

How does Aura Biosciences compare to Zai Lab?

Summary

How does Aura Biosciences compare to SELLAS Life Sciences Group?

Summary

How does Aura Biosciences compare to Beam Therapeutics?

Summary

How does Aura Biosciences compare to Nurix Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AURA vs. The Competition

Aura Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aura Biosciences (AURA) Competitors

AURA vs. IMNM, ZLAB, SLS, BEAM, and NRIX

How does Aura Biosciences compare to Immunome?

Which has more volatility & risk, AURA or IMNM?

Do institutionals & insiders have more ownership in AURA or IMNM?

Which has higher valuation & earnings, AURA or IMNM?

Do analysts prefer AURA or IMNM?

Is AURA or IMNM more profitable?

Does the media refer more to AURA or IMNM?

Summary

How does Aura Biosciences compare to Zai Lab?

Does the media favor ZLAB or AURA?

Is ZLAB or AURA more profitable?

Do institutionals and insiders have more ownership in ZLAB or AURA?

Which has better valuation & earnings, ZLAB or AURA?

Which has more volatility and risk, ZLAB or AURA?

Do analysts prefer ZLAB or AURA?

Summary

How does Aura Biosciences compare to SELLAS Life Sciences Group?

Do institutionals & insiders believe in SLS or AURA?

Does the media prefer SLS or AURA?

Is SLS or AURA more profitable?

Do analysts rate SLS or AURA?

Which has more risk & volatility, SLS or AURA?

Which has stronger earnings and valuation, SLS or AURA?

Summary

How does Aura Biosciences compare to Beam Therapeutics?

Is BEAM or AURA more profitable?

Do insiders & institutionals believe in BEAM or AURA?

Which has higher valuation & earnings, BEAM or AURA?

Which has more risk & volatility, BEAM or AURA?

Do analysts recommend BEAM or AURA?

Does the media favor BEAM or AURA?

Summary

How does Aura Biosciences compare to Nurix Therapeutics?

Is AURA or NRIX more profitable?

Which has better earnings and valuation, AURA or NRIX?

Do insiders & institutionals hold more shares of AURA or NRIX?

Which has more volatility and risk, AURA or NRIX?

Do analysts prefer AURA or NRIX?

Does the media favor AURA or NRIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AURA vs. The Competition

Aura Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools